Hugh Taylor, MD

About

Women whose uterine lining will not thicken enough to accept an embryo send their charts to Hugh Taylor from outside Connecticut. Thin endometrium — a lining that stays stubbornly thin after stimulation, so transfers keep failing — is the referral problem he sees most, and it is the reason a patient in her fourth failed transfer ends up in New Haven rather than at the clinic down the road. Endometriosis is the other half of his panel, and his approach to both conditions is the same: whatever drug mechanism the laboratory has most recently worked out, plus the surgery required to make the uterus capable of carrying.

He runs the department that employs him. Taylor is chair of Yale’s Obstetrics, Gynecology and Reproductive Sciences department and holds its Anita O’Keeffe Young professorship, with a second professorship in Molecular, Cellular and Developmental Biology, and he is Chief of Obstetrics and Gynecology at Yale New Haven Hospital. His Yale listing records both adult and adolescent patients, which is unusual on a fertility panel and fits an endometriosis practice where deep disease often starts before a patient is thinking about pregnancy. He has held continuous NIH funding for more than 20 years; the department receives more than $5 million a year from the agency, which funds the laboratories rather than the clinic.

The research behind his clinical work is specific enough to name. He identified HOX gene regulation in the endometrium and in uterine fibroids, worked out epigenetic markers of progesterone resistance in endometriosis and the role of TET3 and microRNA signalling in the disease, showed that bone-marrow-derived progenitor cells take part in postpartum uterine remodeling (Stem Cells, 2021), and leads a phase I/II trial infusing CD133+ bone marrow stem cells for Asherman syndrome (Nature Communications, 2026). He participates in the PRIMROSE program of linzagolix trials for fibroids. His publication record runs past 400 papers, in venues including the New England Journal of Medicine. He was elected to the National Academy of Medicine in 2016, received an election to the body listed on his Yale record as the AAP in 2024, took the Society for Gynecologic Investigation’s Distinguished Scientist Award in 2020, the IVI Foundation’s reproductive research prize in 2013, and the Endometriosis Association’s Honored Person award in 2012.

Clinical Expertise

Deep and superficial endometriosis. Medical suppression and excision surgery integrated with a fertility plan, for pain, for stage III-IV disease, and for patients whose ovarian reserve has to survive the operation.

Refractory thin endometrium. Evaluation of a lining that fails to proliferate, and management of the transfers that follow it. This is the problem he accepts out-of-state referrals for.

Asherman syndrome and uterine reconstruction. Intrauterine adhesion lysis, with stem cell infusion available to him through an active clinical trial rather than as an experimental favor.

Fibroids. Surgical management plus enrolment in the drug trials — patients who want to avoid myomectomy can be considered for a trial agent.

Recurrent implantation loss. Diagnosis of the implantation-side causes, working with Reshef Tal’s lab on endometrial receptivity within the same division.

Why Choose Dr. Taylor

The institutional weight is documented, not claimed. Election to the National Academy of Medicine in 2016 and the ASRM presidency in 2020-2021 are both dated facts about where he sits in the field. The presidency also means the guidelines he practices under are ones he helped write.

Twenty years of NIH review behind his judgment. Continuous agency funding for over two decades means his protocols have been externally assessed year after year, not once.

Surgery and drugs in one consult. Endometriosis care usually gets split between an excision surgeon and an IVF doctor. His stated approach combines the newest medical therapy with the operation when the operation is what makes a difference.

A trial you can actually join. The CD133+ infusion study for Asherman syndrome is running where he practices, which puts uterine-regeneration therapy inside reach for adhesive disease rather than overseas.

Professional Affiliations

National Academy of Medicine, member (elected 2016). American Association of Physicians, associate member (2024). American Society for Reproductive Medicine, president 2020-2021. Society for Gynecologic Investigation, Distinguished Scientist Award 2020. Endometriosis Association, Honored Person 2012. IVI Foundation Best Research in Reproductive Medicine award 2013. He trained entirely at Yale and Connecticut institutions — BA in molecular biophysics and biochemistry at Yale (1983), MD at the University of Connecticut (1988), obstetrics and gynecology residency at Yale-New Haven Hospital (1992), then Yale fellowships in 1996 and 1998. Board certification is not recorded in the program material we hold for him, so confirm it directly if it matters to your choice.

Suitable For

• Endometriosis patients whose pain or anatomy is the barrier, including those told to operate before trying, and those who want to protect ovarian reserve while doing it
• Patients with repeated transfers against a thin lining, where the embryo has not been the problem
• Asherman syndrome after D&C, myomectomy or uterine surgery, particularly where adhesions have returned after a first lysis
• Complex gynecologic endocrine cases needing a department chair’s read rather than a second clinic opinion